Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Atazanavir
Drug ID BADD_D00176
Description Atazanavir (formerly known as BMS-232632) is an antiretroviral drug of the protease inhibitor (PI) class. Like other antiretrovirals, it is used to treat infection of human immunodeficiency virus (HIV). Atazanavir is distinguished from other PIs in that it can be given once-daily (rather than requiring multiple doses per day) and has lesser effects on the patient's lipid profile (the amounts of cholesterol and other fatty substances in the blood). Like other protease inhibitors, it is used only in combination with other HIV medications. The U.S. Food and Drug Administration (FDA) approved atazanavir on June 20, 2003.
Indications and Usage Used in combination with other antiretroviral agents for the treatment of HIV-1 infection, as well as postexposure prophylaxis of HIV infection in individuals who have had occupational or nonoccupational exposure to potentially infectious body fluids of a person known to be infected with HIV when that exposure represents a substantial risk for HIV transmission.
Marketing Status Prescription; Discontinued
ATC Code J05AE08
DrugBank ID DB01072
KEGG ID D07471
MeSH ID D000069446
PubChem ID 148192
TTD Drug ID D07IQS
NDC Product Code 42385-921; 65862-713; 0003-3631; 70518-1365; 70710-1052; 70771-1591; 65862-710; 69097-443; 0003-3622; 69097-444; 65862-711; 11014-0175; 69097-446; 70771-1592; 69238-1137; 16714-860; 31722-654; 42385-922; 42385-920; 0003-3638; 70771-1593; 70710-1051; 0003-3624; 31722-653; 65862-712; 69097-445; 31722-655; 69238-1136; 16714-861; 69238-1138; 70710-1050; 69238-1135; 16714-862; 70518-2832; 0904-6875
Synonyms Atazanavir Sulfate | Reyataz | Atazanavir | 3,12-bis(1,1-dimethylethyl)-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6-((4-(2-pyridinyl)phenyl)methyl)-2,5,6,10,13-pentaazatetradecanedioic acid dimethyl ester | CGP 75176 | CGP75176 | CGP-75176 | CGP 73547 | CGP-73547 | CGP73547 | CGP 75355 | CGP75355 | CGP-75355 | CGP 75136 | CGP75136 | CGP-75136 | BMS-232632-05 | BMS 232632 05 | BMS23263205 | BMS 232632 | 232632, BMS | BMS-232632 | BMS232632
Chemical Information
Molecular Formula C38H52N6O7
CAS Registry Number 198904-31-3
SMILES CC(C)(C)C(C(=O)NC(CC1=CC=CC=C1)C(CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)C(C(C)(C)C)N C(=O)OC)O)NC(=O)OC
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal discomfort07.01.06.001--Not Available
Abdominal distension07.01.04.001--
Abdominal pain07.01.05.0020.011024%
Abdominal pain upper07.01.05.0030.011024%
Abortion spontaneous18.01.04.0010.019292%Not Available
Agitation17.02.05.012; 19.06.02.001--
Alanine aminotransferase increased13.03.01.0030.008268%
Alopecia23.02.02.001--
Amenorrhoea21.01.02.001; 05.05.01.002--
Amnesia19.20.01.001; 17.03.02.001--
Amylase increased13.05.01.009--
Angioedema23.04.01.001; 10.01.05.009--Not Available
Anxiety19.06.02.002--
Aphthous ulcer07.05.06.002--Not Available
Arrhythmia02.03.02.0010.005512%Not Available
Arthralgia15.01.02.001--
Aspartate aminotransferase increased13.03.01.0060.005512%
Asthenia08.01.01.001--Not Available
Atrial fibrillation02.03.03.0020.008268%
Atrioventricular block02.03.01.002--Not Available
Atrioventricular block complete02.03.01.003--
Atrioventricular block second degree02.03.01.005--
Atrophy08.03.04.001--Not Available
Azotaemia20.01.01.0010.013780%Not Available
Back pain15.03.04.005--
Basedow's disease10.04.08.004; 06.09.04.003; 05.02.02.003--Not Available
Bladder pain20.02.02.0010.008268%Not Available
Blood bilirubin increased13.03.01.0080.027560%
Blood creatinine increased13.13.01.0040.013780%
Blood triglycerides increased13.12.03.001--Not Available
The 1th Page    1 2 3 4 5    Next   Last    Total 9 Pages